Research programme: chronic lymphocytic leukaemia therapy - InDex Pharmaceuticals

Drug Profile

Research programme: chronic lymphocytic leukaemia therapy - InDex Pharmaceuticals

Alternative Names: DIMS 9022

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator InDex Pharmaceuticals
  • Class Oligonucleotides
  • Mechanism of Action Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 14 Mar 2017 InDex Pharmaceuticals receives patent allowance for chronic lymphocytic leukaemia therapy in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-lymphocytic-leukaemia in Sweden
  • 21 Apr 2009 Preclinical trials in Chronic lymphocytic leukaemia in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top